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Abstract
Background and Aim
Social difficulties and problems related to eating behaviour are common features of both
anorexia nervosa (AN) and bulimia nervosa (BN). The aim of this study was to examine the
impact of intranasal oxytocin on consummatory behaviour and emotional recognition in
patients with AN and BN in comparison to healthy controls.
Materials
A total of 102 women, including 35 patients with anorexia nervosa (AN), 34 patients with
bulimia nervosa (BN), and 33 healthy university students of comparable age and intelli-
gence, participated in a double-blind, single dose placebo-controlled cross-over study. A
single dose of intranasal administration of oxytocin (40 IU) (or a placebo) was followed by
an emotional recognition task and an apple juice drink. Food intake was then recorded for
24 hours post-test.
Results
Oxytocin produced no significant change in appetite in the acute or 24 hours free living set-
tings in healthy controls, whereas there was a decrease in calorie consumption over 24
hours in patients with BN. Oxytocin produced a small increase in emotion recognition sensi-
tivity in healthy controls and in patients with BN, In patients with AN, oxytocin had no effect
on emotion recognition sensitivity or on consummatory behaviour.
Conclusions
The impact of oxytocin on appetite and social cognition varied between people with AN and
BN. A single dose of intranasal oxytocin decreased caloric intake over 24 hours in people
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Introduction
Oxytocin is now recognised as having a central role in the neural circuits involved in social
behaviour, appetite, anxiety, and stress [1,2]. These features are also characteristic of people
with an eating disorder, which raises the possibility that oxytocin is involved in the pathophysi-
ology of the disorder [3,4]. During the starvation phase of anorexia nervosa (AN), the levels of
oxytocin in the cerebrospinal fluid are decreased [5–7]. There are changes in the release of oxy-
tocin in response to a meal in both the acute illness and post-recovery conditions [8]. More-
over, an intranasal adminstration of oxytocin produces changes in the attentional processing of
cues that are salient for people with AN. For example, the vigilance toward food and body
image stimuli is reduced [9]. In addition, the attentional bias toward negative facial emotions
(disgust, anger) was modified by oxytocin in AN [10]. These findings suggest that oxytocin sys-
tems may be involved in fear-related stimuli and social cue processing in AN patients.
Meanwhile, fewer studies have investigated the oxytocin sytem in bulimia nervosa (BN) or
in binge eating disorders although some of the features of these conditions also suggest a possi-
ble dysfunction in oxytocin systems. Oxytocin has been demonstrated to be an important pep-
tide for body weight regulation [11,12]. Animal studies suggest that oxytocin is involved in
weight control [13,14] and is particularly involved in inhibiting the appetite for sugar and car-
bohydrates [11,15]. Oxytocin receptor antagonist injections in wild-type mice produced a pref-
erence for sucrose over fat [16]. Oxytocin receptor knockout animals consume greater
amounts of sweet solutions than wild types [17] and develop late onset obesity [18–20]. Ani-
mals engineered not to express oxytocin overconsume sweetened food [21] and carbohydrates
[22]. Oxytocin expression was down regulated upon long-term intermittent exposure to sugar,
which may represent a form of neural adaptation to a high sugar diet [23]. Mice with dietary-
induced obesity exhibit functional abnormalities in the oxytocin systems. In humans, the
administration of oxytocin in obese men produced weight loss [24]. Moreover, a recent study
on healthy men found that oxytocin reduced the intake of high sugar snacks [25,26]. To our
knowledge, there has been no study investigating oxytocin function in patients with BN or
binge eating disorders.
In addition to playing a key role in appetite, oxytocin is involved in social and emotional
processing. Problems that involve social emotional cognition may underpin some of the inter-
personal difficulties in patients with eating disorders, such as a reduction in emotional expres-
sion in patients with AN and problems with trust and conflict in patients with BN, which are
thought to contribute to the maintainance of the disorders [27]. Social cognition is complex
and includes various subprocesses. A recent meta-analysis of the various components of social
cognition in patients with eating disorders found an impairment in most of the domains of
social functioning [28]. Emotional recognition was impaired in patients with eating disorders
but with a large variation observed between tasks, and the weakest effects were observed for
static photographs of faces. To our knowledge, a more ecologically valid technique to measure
the sensitivity for emotional discrimination with dynamically changing facial expressions has
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yet to be used to examine eating disorders. In this study, we used this experimental paradigm
to compare the emotional recognition sensitivity between people with AN or BN and healthy
controls following a single dose of placebo or oxytocin.
The aim of this study was to examine the impact of an intranasal oxytocin challenge test on
two possible maintaining factors of eating disorders: problems in appetite control and social
cognition. The first hypothesis was that oxytocin would decrease food consumption. The sec-
ond hypothesis was that social cognition would be improved in the oxytocin condition in
patients with eating disorders.
Materials and Methods
Participants
The protocol for this study was approved by both the Institutional Review Board of the Korean
Food and Drug Association (12061) and the Institutional Review Board of the Seoul Paik Hos-
pital (IIT-2012-096) on September 16th, 2012 (See S1–S4 Texts). Although this is an experi-
mental proof of concept study, and we have established with the regulatory agencies in the UK
that it does not need to registered, we have found that other experts and journals find this con-
fusing. Therefore, we have registered the study in the clinical trial registry [the Clinical
Research Information Service (http://cris.nih.go.kr) (registration number: KCT0000716)]. All
ongoing and related trials for this drug/intervention were registered. All of the participants pro-
vided written informed consent.
One hundred and two women (35 patients with AN, 34 patients with BN, and 33 healthy
university students) completed this double-blind, placebo-controlled cross-over study. The
first participant entered the study on April 4th, 2013, and the last participant completed follow-
up on August 14th, 2014. The patients with AN were recruited from the inpatient ward and the
patients with BN were recruited from the outpatient clinic of the Eating Disorders Clinic of the
Seoul Paik Hospital in Seoul, South Korea. The diagnosis of eating disorder was confirmed by
the Structured Clinical Interview from the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition [29]. All patients satisfied the DSM-5 diagnostic criteria of AN or BN. The
exclusion criteria for comorbidities included active substance use disorder, psychotic disorder
(schizophrenia, schizoaffective, psychosis not otherwise specified), and autism spectrum disor-
der. Patients taking psychiatric medications other than fluoxetine were also excluded.
The healthy controls were undergraduate or graduate students of a comparable age and
intelligence who responded to an advertisement posted in the psychology department at a
women’s university in Seoul, South Korea. The inclusion criteria were healthy females without
a history of medical or psychiatric illness and a minimum age of 17. We screened all healthy
participants for eating disorders with the SCOFF questionnaire [30]. The exclusion criteria for
the healthy controls included a self-reported history of major depression, bipolar, panic, or psy-
chotic disorders, substance dependence, epilepsy, eating disorder, autism spectrum disorder,
traumatic brain injury, and taking medications (including contraceptives). We also excluded
the participants who were smokers, homosexual, or parous because these conditions may inter-
fere with oxytocin functioning.
The healthy controls and patients with BN who had their period were tested during the fol-
licular phase of their menstrual cycle (approximately days 3 through 12). None of the patients
with AN were menstruating. The participants were compensated for their travelling expenses
and time.
The degree of the eating psychopathology for all participants (weight, shape, eating con-
cerns, and dietary restraint) was evaluated using the Korean version of the Eating Disorder
Examination self-report version Questionnaire (EDE-Q) [31]. Depression and anxiety were
Oxytocin on Intake and Emotion in Eating Disorders
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assessed for each subject by using the standardized Korean versions of the Beck Depression
Inventory (BDI) [32] and the Spielberger State and Trait Anxiety Inventory (STAI) [33],
respectively. The Korean version of the Ward 7-subtest short form of the Wechsler Adult Intel-
ligence Scale [34] was used to measure the IQ of all participants.
A consort diagram is shown in Fig 1 (See S5 Text).
Oxytocin preparation
The intranasal oxytocin spray was formulated by JW Pharmaceuticals (Seoul, South Korea)
from oxytocin powder (Hemmo Pharmaceuticals, Mumbai, India). The solution was prepared
by combining 35.2 mg of oxytocin (568 U) with 300 mL of 0.9% sodium chloride solution and
adjusting the pH to 4.01 with 10× diluted acetic acid. The placebo spray (pH 4.01) was formu-
lated with 0.9% sodium chloride solution and acetic acid, without the addition of oxytocin. The
filtered and sterilized solutions were sealed in individual vials (1.5 mL each) and were frozen
for storage. On the day of use, the vials were thawed and kept in a refrigerator at 4°C until
required. A clinician prepared the nasal spray by transferring the oxytocin or the placebo from
Fig 1. A consort diagram describing the participants in the study.
doi:10.1371/journal.pone.0137514.g001
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the vial into a nebulizer. The nebulizer was primed and given to the participants, who self-
administered the nasal spray while being monitored by the clinician.
Dynamic facial morphing task
The dynamic facial morphing task consisted of video clips showing computer-morphed faces.
Neutral faces morphed into emotional faces showing sad, fearful, angry, or happy expressions
with 50 gradual levels of each emotion, adhering to the experimental paradigm described by
Joormann and Gotlib [35]. The task was formulated by one of the authors [36] and was con-
ducted using MATLAB version R2010 (Mathworks, Natick, MA, USA) in conjunction with the
Psychophysics Toolbox version 2.54 [37,38]. The facial stimuli were (12.7 × 16.9 cm) in size
and were presented in colour in the middle of the screen with a grey background. The animated
morphs were presented on a high-resolution 15-inch monitor, and the distance between the
participant and the monitor was of about 60 cm.
The participants were asked to respond as quickly as possible with a keyboard stroke when
they noticed any emotion in the face. The stimuli included faces of two men and two women
taken from a database of Korean actors and actresses in their 20s to 40s [39]. Four practice tri-
als and 16 experimental trials, which comprised four emotions from each of the four chosen
actors/actresses, were conducted. The outcome was measured as the intensity level at which
emotions were accurately identified (; emotional sensitivity).
In the task, a fixed ‘+’ was initially shown for 500 ms in the centre of the screen, after which
a neutral facial expression with 0% emotional intensity was shown for 500 ms. Progressive
facial expressions of a 2% higher emotional intensity were shown at 500 ms intervals until the
participant detected the presence of an emotion in the facial expression and reacted by pressing
the space bar on the computer keyboard. The facial morphing was stopped, and the participant
identified the emotion as ‘sadness’, ‘fear’, ‘anger’, or ‘happiness’ using the number keys ‘0’, ‘1’,
‘2’, or ‘3’, respectively, after which the next trial started immediately (Fig 2).
Procedures
Each participant visited the laboratory twice for testing: once in the placebo condition and
once in the oxytocin condition. Neither the participant nor the researchers involved were
informed about the drug assignment of the day. The order in which to administer the placebo
or the oxytocin to each participant was determined randomly (1:1) by the project coordinator,
Fig 2. Dynamic facial morphing task. In the task, a fixed ‘+’ was initially shown for 500 ms in the centre of
the screen, after which a neutral facial expression with 0% emotional intensity was shown for 500 ms.
Progressive facial expressions of a 2% higher emotional intensity were shown at 500 ms intervals until the
participant detected the presence of an emotion in the facial expression and reacted by pressing the space
bar on the computer keyboard. The facial morphing was stopped, and the participant identified the emotion as
‘sadness’, ‘fear’, ‘anger’, or ‘happiness’ using the number keys ‘0’, ‘1’, ‘2’, or ‘3’, respectively, after which the
next trial started immediately. The photograph is from a database published [39].
doi:10.1371/journal.pone.0137514.g002
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who was not involved in conducting the experiment, using Microsoft Excel as follows: (1) The
RAND function was used to generate a random number between 0 and 1, (2) If the generated
number was smaller than 0.5, the participant was given the placebo first and (3) If the gener-
ated number was greater than or equal to 0.5, the participant was given oxytocin first.
The patients with eating disorders were provided with meal plans with fixed-size portions
during the experimental period in order to not influence the drug’s effect on calorie consumed
during 24 hours. The patients with AN did not receive any direct support for eating during the
24 hours following the experiments on the inpatient ward. The patients with BN had meal
plans focused on preventing binging and purging while supplying adequate energy to maintain
a healthy weight, and they were instructed with a meal routine during the experimental period.
Healthy controls were instructed to continue their routine diet during the 24 hours after the
experiments.
The participants were tested in a private room at the Seoul Paik Hospital at 14:30. They
were instructed to abstain from consuming alcohol or caffeine on the test day and to abstain
from consuming food and drink (other than water) for 2 hours before the tests. Upon arrival,
the participants completed baseline measures of physical symptoms, including abdominal,
neurological, dermatological, and cardiac symptoms. The oxytocin and the placebo were self-
administered intra-nasally under the supervision of a clinician, and the neuropsychological
tasks were started 45 minutes later. A dose of 40 IU of oxytocin was chosen based on the results
of a recent review that found the short-term use of intranasal oxytocin administered to male
and female humans in dosages of up to 40 IU (per dose) to result in no detectable, subjective
changes in a controlled research setting [40]. The nasal administration of oxytocin followed the
guidelines established by Guastella et al. [41]. 90 min after the drug had been administered, the
participants were asked to drink a carton of apple juice (Delmont, 190 mL per carton, 60 kcal).
They were asked to consume as much of the juice as possible, as quickly as they were comfort-
able with, within a 20 min period. Finally, the participants completed an adverse symptom
questionnaire. Over 24 hours following the experiment, the participants recorded a food diary
to report every food and beverage items consumed, including the type, quantity, and approxi-
mate time and they sent back their diaries next day through their smartphones. A researcher
who was blind to all the study procedures counted the calorie intake from the participant’s
diary. The second appointment was scheduled at least four days and at most seven days after
the first appointment. The same procedure was repeated during the next visit, but the content
of the spray differed according to the randomization plan.
Statistical analysis
Sample size was calculated to detect two-way interaction effect using a repeated-measures
ANOVA based on mixed effect model with 95% power and correlation among repeated mea-
sure = 0.5 across 3 groups. The results showed that 22 subjects would be needed with a medium
effect (Δη2 = 0.06) and 129 subjects would be needed with a small effect (Δη2 = 0.01) per each
group to detect significant interaction effect.
At the placebo condition, one-way ANOVAs were calculated for the amount of juice drank,
calories consumed during 24 hours, and sensitivity to emotional recognition to examine the
baseline differences among the diagnostic subtype (AN, BN, controls), as we valued the find-
ings at the baseline.
We explored a mixed factor analysis (ANOVA) defining the following factors: 1) pre-post
measure for drug (intra-factor); 2) drug (oxytocin-placebo) (intra-factor); and 3) diagnosis
(AN-BN-controls) (inter-factor). As the pre-post measure was not significant on outcome
measures of juice intake (p = 0.825), calories consumed (p = 0.908) and emotional intensity
Oxytocin on Intake and Emotion in Eating Disorders
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(p = 0.859), we excluded carry-over effect of pre-post measure. Therefore, drug and diagnosis
were included as factors in repeated measures ANOVA. For the food intake outcomes of the
immediate juice intake and the calories consumed over 24 hours, we examined 2(drug) × 3
(diagnosis) repeated-measures ANOVAs and then made an independent analysis stratified by
diagnosis to cope with low power due to small sample size.
As the level of difficulty of the morphing task was low, the main dependent variable we used
was emotional intensity not accuracy. The sensitivity of emotional recognition was restricted to
trials in which facial expressions were correctly identified. The emotional intensity was con-
verted into the corrected emotional intensity which was calculated from the relative emotional
intensity at the point of identification of an emotion.
The responses to the emotional stimuli were investigated via two way 2 (drug) × 3 (diagnosis)
repeated-measures analyses of variance (ANOVAs) on overall emotion, and then repeated-mea-
sures ANOVAs for each of the emotions (sad, fear, angry and happy) stratified by diagnosis were
carried out. Post-hoc pairwise comparisons or simple main effect analyses were performed for
significant main or interaction effects.
The data shown are presented as the mean and effect size (ES) if appropriate [Cohen’s d for
paired t-tests; partial eta squared (Δη2) for ANOVA]. Cohen’s d was described as negligible
(< 0.20), small (< 0.50), medium ( 0.50 and< 0.8), or large ( 0.8) [42]. Δη2 was described
as small (<0.01), medium (<0.059), or large (<0.138) [43]. P-values<0.05 were considered to
be significant, and two-tailed tests were used. The statistical analyses were performed using
SPSS 19.0 (IBM Inc., Chicago, IL, USA).
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of the participants are shown in Table 1. The age
(p = 0.754) and IQ levels (p = 0.243) did not differ among the diagnoses. The mean age of
onset (p = 0.957) and the mean duration of the illness (p = 0.243) did not differ between
patients with AN and patients with BN. Patients with AN and BN had higher levels of depres-
sion and anxiety than controls [all p<0.001, BN = AN>HC in post hoc Tukey]. The eating dis-
order psychopathology differed among the diagnoses [all p<0.001: in post hoc Tukey,
BN>AN>HC in global score and eating concern scale, BN>AN = HC in shape and weight
concern scales, AN = BN>HC in restraint scale].
Immediate consummatory behaviour of juice intake
Table 2 shows the results of immediate test meal of juice intake after receiving oxytocin or pla-
cebo. In the baseline condition, the amount of juice drank was significantly different among
the groups [F(2,99) = 8.738, p<0.01; Δη2 = 0.150]. The post hoc tests showed that both the
patients with AN [p<0.001] and BN [p = 0.030] drank a lower amount of juice than the con-
trols did.
The two-way 2 (drug) × 3 (diagnosis) repeated measures ANOVA showed a small effect of
oxytocin [F(1,99) = 4.469, p = 0.037, Δη2 = 0.043] and large effect of diagnosis [F(2,99) =
11.600, p<0.001, Δη2 = 0.190]. In the repeated measures ANOVAs stratified by diagnosis,
there was no significant effect of oxytocin on juice intake in any diagnostic subtype.
Caloric intake for 24-hours
Table 2 shows the caloric intake over a period of 24 hours after receiving oxytocin or placebo.
In the baseline condition, the amount of calorie intake during 24 hours was different among
Oxytocin on Intake and Emotion in Eating Disorders
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the groups [F(2,99) = 6.581, p = 0.002, Δη2 = 0.120]. The post hoc tests showed that the patients
with BN reported eating more calories than the patients with AN during the 24-hour period
(p = 0.001 for AN vs BN; p = 0.372 for AN vs HC; p = 0.082 for BN vs HC).
The two-way 2 (drug) × 3 (diagnosis) repeated-measures ANOVA showed a significant
interaction between diagnosis and drug [F(2,99) = 4.736, p = 0.011, Δη2 = 0.089], but the effects
of each of the factors were weak [for diagnosis, F(2,99) = 3.099, p = 0.050, Δη2 = 0.060; for
drug, F(1,99) = 2.835, p = 0.095, Δη2 = 0.028]. In the repeated measures ANOVAs stratified by
diagnosis, there was a significant effect of drug in patients with BN [F(1,33) = 6.389, p = 0.016,
Δη2 = 0.162]. The patients with BN consumed fewer calories after receiving oxytocin
(p = 0.016, d = 0.560). There was no significant effect of oxytocin either in healthy controls
(p = 0.384) or patients with AN (p = 0.145).
Sensitivity of emotional recognition
The thresholds for the facial emotion identification in the oxytocin condition are depicted in
Table 3. In the baseline condition, there was no effect of diagnosis on the threshold of emo-
tional recognition [F(2,99) = 0.662, p = 0.518, Δη2 = 0.013]. There was an effect of emotional
type [F(3,97) = 171.584, p<0.001, Δη2 = 0.844], in that happy emotion was easier to identify
and angry emotion was less easy regardless of diagnostic subtype.
As the sample size was small, we made 2 (drug) × 3 (group) repeated-measures ANOVAs
on overall emotion and then made an independent analysis stratified by diagnosis. The two-
way 2 (drug) × 3 (group) repeated-measures ANOVAs demonstrated a main effect of drug [F
(1,99) = 5.172, p = 0.025, Δη2 = 0.053] but no effect of group (p = 0.949) (Fig 3).
In the stratified analysis by diagnosis, there was a small effect of drug in overall emotional
recognition [F(1,32) = 4.530, p = 0.041, Δη2 = 0.124] in healthy controls. In the post hoc analy-
sis, the sensitivity to overall emotional recognition was increased in the oxytocin condition in
the healthy controls [t(32) = 2.128, p = 0.041, d = 0.311]. In the following repeated-measures
Table 1. Demographic and clinical characteristics of healthy controls and the patients with anorexia nervosa and bulimia nervosa.
Characteristics AN (a, n = 35) BN (b, n = 34) HC (c, n = 33) F(2,99) p Tukey HSD
Age, years 21.97(8.41) 23.03(5.17) 22.64(2.28) 0.283 0.754 NA
Age of onset, years 18.80(5.52) 18.74(4.38) NA T(67) = -0.054 0.957 NA
Duration of illness, months 43.26(62.13) 57.59(34.72) NA T(67) = 1.178 0.243 NA
WAIS, IQ 107.11(12.38) 106.62(11.91) 110.79(5.54) 1.581 0.211 NA
BMI 15.07(2.41) 20.24(2.45) 20.86(2.14) 63.334 <0.001 b = c>a
BDI 21.97(12.99) 18.29(10.94) 7.28(6.90) 16.788 <0.001 a = b>c
STAI
State 55.85(13.62) 53.26(12.78) 43.44(11.27) 8.746 <0.001 a = b>c
Trait 54.94(13.29) 53.26(12.79) 43.75(11.16) 10.972 <0.001 a = b>c
EDE-Q
Restraint 2.21(1.77) 2.32(1.78) 0.76(0.76) 10.927 <0.001 a = b>c
Eating Concern 1.88(1.69) 2.76(1.76) 0.56(0.77) 18.613 <0.001 b>a>c
Shape Concern 2.38(1.49) 3.56(1.82) 1.52(1.16) 15.343 <0.001 b>a = c
Weight Concern 2.73(1.45) 3.88(1.60) 2.21(1.29) 11.600 <0.001 b>a = c
Global 2.30(1.45) 3.13(1.48) 1.26(0.87) 17.413 <0.001 b>a>c
AN, anorexia nervosa; BN, bulimia nervosa; HC, healthy controls; WAIS: Wechsler Adult Intelligent Scale; IQ, Intelligent Quotient; BMI, body mass index;
EDE-Q, Eating Disorder Examination Questionnaire; BDI, Beck Depression Inventory; STAI-State, Spielberger State and Trait Anxiety Inventory State
score; STAI-Trait, Spielberger State and Trait Anxiety Inventory Trait score; NA, Not applicable
doi:10.1371/journal.pone.0137514.t001
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ANOVAs for each of the emotions in the healthy controls, the effect of oxytocin was significant
in sad emotion [F(1,32) = 5.792, p = 0.022, Δη2 = 0.153]. In the post hoc analysis, the sensitivity
to sad emotion recognition was increased in the oxytocin condition in the healthy controls
(p = 0.022, d = 0.280).
In the patients with BN, there was a tendency of drug effect on overall emotional recogni-
tion [F(1,33) = 3.461, p = 0.072, Δη2 = 0.095]. In the post hoc analysis, oxytocin had a tendency
to increase the sensitivity to overall emotional recognition in the patients with BN [t(32) =
2.128, p = 0.052, d = 0.315]. In the following repeated-measures ANOVAs for each of the emo-
tions, the effect of oxytocin was significant in sad emotion in the patients with BN [F(1,33) =
5.144, p = 0.031, Δη2 = 0.135]. In the post hoc analysis, the sensitivity to sad emotion recogni-
tion was increased in the oxytocin condition in the patients with BN (p = 0.031, d = 0.399).
In the patients with AN, there was no effect of drug [F(1,34) = 0.348, p = 0.559, Δη2 =
0.010]. In the following repeated-measures ANOVAs for each of the emotions, there was no
effect of oxytocin on the sensitivity to any of the emotion recognition in the patients with AN.
Discussion
The aim of this study was to examine the impact of an intranasal oxytocin challenge test on
two possible maintaining factors of eating disorders: problems in appetite control and social
cognition. A single dose of intranasal oxytocin decreased caloric intake over 24 hours with a
moderate effect in patients with BN. The immediate effect of oxytocin on intake was not signif-
icant in any of groups. Oxytocin increased emotion recognition particularly for sad expressions
in patients with BN and in healthy women. No effects of oxytocin were found in either out-
comes in patients with AN.
Fig 3. Emotional intensity for accurate emotion identification of total emotion under oxytocin/placebo
conditions. Emotional intensity for accurate emotion identification of total emotion under oxytocin/placebo
conditions. There was a main effect of drug [F(1,99) = 5.172, p = 0.025, Δη2 = 0.053], in which oxytocin
increased the sensitivity of overall emotional recognition with a small effect size in the healthy women
(d = 0.311) and the patients with BN (d = 0.315). AN, anorexia nervosa; BN, bulimia nervosa.
doi:10.1371/journal.pone.0137514.g003
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The most prominent finding in this study was that patients with BN consumed fewer calo-
ries over 24 hours after a single dose of intranasal oxytocin. The mechanisms underlying oxyto-
cin’s reduction of caloric intake, particularly in the BN group, have not yet been defined.
Previous work found that oxytocin reduced hedonic eating in test meal conditions in men [25,
26]. Possible mechanism underpinning this effect may be by reducing emotional eating
through reducing stress [44]. A study of anti-obesity effects of oxytocin in free living conditions
in obese rats [12] suggested that oxytocin may also affect energy homeostasis [11], glucose
metabolism and lipid metabolism [12]. The positive results of this proof of principle experi-
mental study suggest that it may be useful to further examine the role of oxytocin in patients
with BN.
In addition to the impact on appetite and metabolism, oxytocin has an impact on social cog-
nition. We used dynamic facial expressions to investigate emotion recognition as these resem-
ble naturalistic interpersonal situations better than static facial expressions. We found that
oxytocin improved emotion recognition for dynamic facial expressions, particularly for nega-
tive emotions in patients with BN and in healthy women. This result is consistent with a previ-
ous study [45] in which administering oxytocin enhanced overall emotion recognition of faces
in healthy humans. Our results are also consistent with a previous study that used a similar
emotion recognition tasks with morphing faces, in which oxytocin increased the sensitivity to
emotion recognition in healthy men [46]. It is interesting that intranasal oxytocin did not
change emotion recognition sensitivity in patients with AN even though they had a relatively
higher dose per body weight of oxytocin due to their low weight. We previously reported an
increase in methylation in the MT2 region of the OXTR promoter in patients with AN [47].
Therefore, it is possible that this reduced functionality accounts for the limited overall effects
of oxytocin observed in this group.
There are some limitations in this study that need to be considered. First, we used a self-
reported diary to record food consumption during the 24 hours observation period which may
have decreased the sensitivity of the outcome measure. Objective measures of caloric intake
may be more precise. Second, the technology used to examine the eating behaviour was simple.
A design including a "taste test", a covert method of measuring the consumption of high fat,
sugar palatable foods, would have been of value to test the hypothesis that oxytocin has a spe-
cific effect on hedonic eating. Similarly it would have been of value to measure the trait of food
addiction. Third, three patients with AN and 3 patients with BN were taking stable dose of flu-
oxetine in our study, which may have confounded the results. It is common in clinical practice
that patients with eating disorders take antidepressants which makes it ecologically relevant to
include them in this sample. Furthermore, an additional analysis found no differences in the
outcome measures in the response of this subgroup to the non-medicated patients. Fourth, it is
possible that a more challenging social cognition task, such as “reading the mind” task, may
increase the sensitivity to find differences. Lastly, other minor limitation was that the sample
size was too small to detect a small interaction effect with a repeated-measures ANOVA.
Therefore, it is possible that we could not detect any interaction effect on emotional intensity
with this sample size.
In conclusion, the impact of oxytocin on appetite and social cognition varied between peo-
ple with AN and BN. A single dose of intranasal oxytocin decreased caloric intake over 24
hours in people with BN. Moreover, people with BN showed enhanced emotional sensitivity
under oxytocin condition similar to healthy controls. Those effects of oxytocin were not found
in patients with AN.
Oxytocin on Intake and Emotion in Eating Disorders
PLOS ONE | DOI:10.1371/journal.pone.0137514 September 24, 2015 12 / 15
Supporting Information
S1 Dataset. Raw data for participants.
(SAV)
S1 Text. Informed consent_English.
(DOC)
S2 Text. Informed consent_Korean.
(DOC)
S3 Text. Protocol_English.
(DOC)
S4 Text. Protocol_Korean.
(DOC)
S5 Text. Consort checklist.
(DOC)
Author Contributions
Conceived and designed the experiments: YK JT. Performed the experiments: YK JK. Analyzed
the data: YK JE. Contributed reagents/materials/analysis tools: JY. Wrote the paper: YK JT.
References
1. Blevins JE, Ho JM (2013) Role of oxytocin signaling in the regulation of body weight. Rev Endocr
Metab Disord 14: 311–329. doi: 10.1007/s11154-013-9260-x PMID: 24065622
2. Insel TR (2010) The Challenge of Translation in Social Neuroscience: A Review of Oxytocin, Vasopres-
sin, and Affiliative Behavior. Neuron 65: 768–779. doi: 10.1016/j.neuron.2010.03.005 PMID: 20346754
3. Maguire S, O’Dell A, Touyz L, Russell J (2013) Oxytocin and Anorexia Nervosa: a review of the emerg-
ing literature. Eur Eat Disorders Rev 21: 475–478.
4. Sabatier N, Leng G, Menzies J (2013) Oxytocin, feeding, and satiety. Front Endocrinol 35: 1–10.
5. Choleris E, Devidze N, Kavaliers M, Pfaff DW (2008) Steroidal/neuropeptide interactions in hypothala-
mus and amygdala related to social anxiety. In: Neumann ID, Landgraf R, editors. Advances in Vaso-
pressin and Oxytocin: From Genes to Behaviour to Disease. pp. 291–303.
6. Demitrack MA, LesemMD, Listwak SJ, Brandt HA, Jimerson DC, Gold PW (1990) CSF oxytocin in
anorexia nervosa and bulimia nervosa: clinical and pathophysiologic considerations. Am J Psychiatry
147: 882–886. PMID: 2356873
7. Lawson EA, Donoho DA, Blum JI, Meenaghan EM, Misra M, Herzog DB, et al. (2011) Decreased noc-
turnal oxytocin levels in Anorexia Nervosa are associated with low bone mineral density and fat mass. J
Clin Psychiatry 72: 1546–1551. doi: 10.4088/JCP.10m06617 PMID: 21903023
8. Lawson EA, Holsen LM, Santin M, Meenaghan E, Eddy KT, Becker AE, et al. (2012) Oxytocin secretion
is associated with severity of disordered eating psychopathology and insular cortex hypoactivation in
Anorexia Nervosa. J Clin Endocrinol Metabol 97: E1898–E1908.
9. Kim YR, Kim CH, Cardi V, Eom JS, Seong Y, Treasure J (2014) Intranasal oxytocin attenuates atten-
tional bias for eating and fat shape stimuli in patients with anorexia nervosa. Psychoneuroendocrinol-
ogy 44: 133–142. doi: 10.1016/j.psyneuen.2014.02.019 PMID: 24703429
10. Kim YR, Kim CH, Park JH, Pyo J, Treasure J (2014) The Impact of Intranasal Oxytocin on Attention to
Social Emotional Stimuli in Patients with Anorexia Nervosa: A Double Blind within-Subject Cross-over
Experiment. Plos One 9: e90721. doi: 10.1371/journal.pone.0090721 PMID: 24603863
11. Chaves VE, Tilelli CQ, Britob NA, Brito MN (2013) Role of oxytocin in energy metabolism. Peptides 45:
9–14. doi: 10.1016/j.peptides.2013.04.010 PMID: 23628372
12. Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier A-L, Petrosino S, et al. (2011) Mecha-
nisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats. Plos One 6.
Oxytocin on Intake and Emotion in Eating Disorders
PLOS ONE | DOI:10.1371/journal.pone.0137514 September 24, 2015 13 / 15
13. Wu Z, Xu Y, Zhu Y, Sutton AK, Zhao R, Lowel B, et al. (2012) An obligate role of oxytocin neurons in
diet induced energy expenditure. PLoS One 7: e45167. doi: 10.1371/journal.pone.0045167 PMID:
23028821
14. Leng G, Onaka T, Caquineau C, Sabatier N, Tobin VA, Takayanagi Y (2008) Oxytocin and appetite.
Prog Brain Res 170: 137–151. doi: 10.1016/S0079-6123(08)00413-5 PMID: 18655879
15. Parker JA, Bloom SR (2012) Hypothalamic neuropeptides and the regulation of appetite. Neurophar-
macology 63: 18–30. doi: 10.1016/j.neuropharm.2012.02.004 PMID: 22369786
16. Olszewski PK, Klockars A, Schioth HB, Levine AS (2010) Oxytocin as feeding inhibitor Maintaining
homeostasis in consummatory behavior. Pharmacology Biochemistry and Behavior 97: 47–54.
17. Amico JA, Vollmer RR, Cai HM, Miedlar JA, Rinaman L (2005) Enhanced initial and sustained intake of
sucrose solution in mice with an oxytocin gene deletion. American Journal of Physiology-Regulatory
Integrative and Comparative Physiology 289: R1798–R1806.
18. Nishimori K, Takayanagi Y, Yoshida M, Kasahara Y, Young LJ, et al. (2008) New aspects of oxytocin
receptor function revealed by knockout mice: sociosexual behaviour and control of energy balance.
Advances in Vasopressin and Oxytocin: From Genes to Behaviour to Disease 170: 79–90.
19. Nishimori K, Young LJ, Guo QX, Wang ZX, Insel TR, et al. (1996) Oxytocin is required for nursing but is
not essential for parturition or reproductive behavior. Proceedings of the National Academy of Sciences
of the United States of America 93: 11699–11704. PMID: 8876199
20. Takayanagi Y, Kasahara Y, Onaka T, Takahashi N, Kawada T, et al. (2008) Oxytocin receptor-deficient
mice developed late-onset obesity. Neuroreport 19: 951–955. doi: 10.1097/WNR.0b013e3283021ca9
PMID: 18520999
21. Miedlar JA, Rinaman L, Vollmer RR, Amico JA (2007) Oxytocin gene deletion mice overconsume palat-
able sucrose solution but not palatable lipid emulsions. American Journal of Physiology-Regulatory
Integrative and Comparative Physiology 293: R1063–R1068.
22. Sclafani A, Rinaman L, Vollmer RR, Amico JA (2007) Oxytocin knockout mice demonstrate enhanced
intake of sweet and nonsweet carbohydrate solutions. American Journal of Physiology-Regulatory Inte-
grative and Comparative Physiology 292: R1828–R1833.
23. Mitra A, Gosnell BA, Schioth HB, Grace MK, Klockars A, et al. (2010) Chronic sugar intake dampens
feeding-related activity of neurons synthesizing a satiety mediator, oxytocin. Peptides 31: 1346–1352.
doi: 10.1016/j.peptides.2010.04.005 PMID: 20399242
24. Zhang G, Bai H, Zhang H, Dean C, Wu Q, Li J, et al. (2011) Neuropeptide exocytosis involving synapto-
tagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron 69:
523–535. doi: 10.1016/j.neuron.2010.12.036 PMID: 21315262
25. Ott V, Finlayson G, Lehnert H, Heitmann B, Heinrichs M, Born J, et al. (2013) Oxytocin Reduces
Reward-Driven Food Intake in Humans. Diabetes 62: 3418–3425. doi: 10.2337/db13-0663 PMID:
23835346
26. Lawson E, Marengi D, DeSanti R, Holmes T, Schoenfeld D, et al. (2015 in press) Oxytocin Reduces
Caloric Intake in Men. Obesity.
27. Arcelus J, HaslamM, Farrow C, Meyer C (2013) The role of interpersonal functioning in the mainte-
nance of eating psychopathology: A systematic review and testable model. Clin Psychol Rev 33: 156–
167. doi: 10.1016/j.cpr.2012.10.009 PMID: 23195616
28. Caglar-Nazali HP, Corfield F, Cardi V, Ambwani S, Leppanen J, Olabintan O, et al. (2014) A systematic
review and meta-analysis of 'Systems for Social Processes’in eating disorders. Neurosci Biobehav Rev
42: 55–92. doi: 10.1016/j.neubiorev.2013.12.002 PMID: 24333650
29. First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured Clinical Interview for DSM-IV-TR Axis
I Disorders-Patient Edition (SCID-I/P). New York: Biometrics Research Department, New York State
Psychiatric Institute.
30. Morgan JF, Reid F, Lacey JH (1999) The SCOFF questionnaire: assessment of a new screening tool
for eating disorders. British Medical Journal 319: 1467–1468. PMID: 10582927
31. Fairburn C, Beglin S (1994) Assessment of eating disorders—Interview or self-report questionnaire. Int
J Eat Disord 16: 363–370. PMID: 7866415
32. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh J (1961) An inventory for measuring depression.
Arch Gen Psychiatry 4: 561–571. PMID: 13688369
33. Spielberger C, Gorsuch R, Lushene R, Vagg P, Facobs G (1983) Manual for the State-Trait Anxiety
Inventory, STAI (Form Y). Palo Alto: Consulting Psychologists Press.
34. Ward LC (1990) Prediction of verbal, performance, and full scale IQs form the seven subsets of the
WAIS-R. J Clin Psychol 46: 436–440. PMID: 2212047
Oxytocin on Intake and Emotion in Eating Disorders
PLOS ONE | DOI:10.1371/journal.pone.0137514 September 24, 2015 14 / 15
35. Joormann J, Gotlib IH (2006) Is this happiness I see? Biases in the identification of emotional facial
expressions in depression and social phobia. J Abnorm Psychol 115: 705–714. PMID: 17100528
36. Yang J (2009) Perceptual and cognitive bias for facial emotion in social anxiety: Yonsei University
Graduate School.
37. Brainard DH (1997) The psychophysics toolbox. Spatial Vision 10: 433–436. PMID: 9176952
38. Pelli DG (1997) The videotoolbox software for visual psychophysics: Transforming numbers into mov-
ies. Spat Vis 10: 437–442. PMID: 9176953
39. Yonsei University Cognitive Science Institute (1998) Development of facial expression and body ges-
tures database. Seoul: Ministry of Education and Science.
40. MacDonald E, Dadds M, Brennan J, Williams K, Levy F, Cauch AJ (2011) A review of safety, side-
effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology
36: 1114–1126. doi: 10.1016/j.psyneuen.2011.02.015 PMID: 21429671
41. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM, et al. (2013) Recommenda-
tions for the standardisation of oxytocin nasal administration and guidelines for its reporting in human
research. Psychoneuroendocrinology 38: 612–625. doi: 10.1016/j.psyneuen.2012.11.019 PMID:
23265311
42. Cohen J (1992) A power primer. Psychological Bulletin 112: 155–159. PMID: 19565683
43. Cohen J (1988) Statistical power analysis for the behavioral sciences. New Jersey: Lawrenced Erl-
baum Associated Inc.
44. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U (2003) Social support and oxytocin interact to
suppress cortisol and subjective responses to psychosocial stress. Biological Psychiatry 54: 1389–
1398. PMID: 14675803
45. Shahrestani S, Kemp AH, Guastella AJ (2013) The Impact of a Single Administration of Intranasal Oxy-
tocin on the Recognition of Basic Emotions in Humans: A Meta-Analysis. Neuropsychopharmacology
38: 1929–1936. doi: 10.1038/npp.2013.86 PMID: 23575742
46. Lischke A, Berger C, Prehn K, Heinrichs M, Herpertz S, Domes G (2012) Intranasal oxytocin enhances
emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroen-
docrinology 37: 475–481. doi: 10.1016/j.psyneuen.2011.07.015 PMID: 21862223
47. Kim YR, Kim JH, Kim MJ, Treasure J (2014) Differential Methylation of the Oxytocin Receptor Gene in
Patients with Anorexia Nervosa: A Pilot Study. PLoS ONE 9: e90721. doi: 10.1371/journal.pone.
0090721 PMID: 24603863
Oxytocin on Intake and Emotion in Eating Disorders
PLOS ONE | DOI:10.1371/journal.pone.0137514 September 24, 2015 15 / 15
